Stay updated on TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin
Sign up to get notified when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.
Latest updates to the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page
- Check2 days agoChange DetectedAdded a new Locations section listing California as a study site. Removed the California Locations entry and the HHS Vulnerability Disclosure text, and updated the page revision from v3.3.2 to v3.3.3.SummaryDifference0.2%
- Check10 days agoChange DetectedThe screenshots show no significant changes to core study content; only metadata such as the last update date appears to be different. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check17 days agoChange DetectedThere are no substantive changes to the core study information between the two screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check31 days agoChange DetectedPublication section wording was revised from 'are about the study results' to 'are about the results of the study,' a minor textual update to the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check39 days agoChange DetectedThe banner regarding government funding and operating status was removed from the page.SummaryDifference0.5%
- Check46 days agoChange DetectedLast update posted date updated to 2025-02-24 with minor textual edits; no changes to study design, eligibility criteria, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
Stay in the know with updates to TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin
Enter your email address, and we'll notify you when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.